Buscar
Emergent BioSolutions Inc
EBSAñadir a la lista de seguimiento
6.800USD
-0.220-3.13%
Cierre 09-18 16:00（ET）
347.81MCap. mercado
PérdidaP/E TTM
Fuera de horario 19:00 (ET)6.800USD-0.030-0.44%
Fuera de horario 19:00 (ET)Más Datos de Emergent BioSolutions Inc Compañía
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Perfil de Emergent BioSolutions Inc
Símbolo de cotizaciónEBS
Nombre de la empresaEmergent BioSolutions Inc
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoPapa (Joseph C)
Número de empleados900
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 15
Dirección300 Professional Dr
CiudadGAITHERSBURG
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal20879
Teléfono12406313200
Sitio Webhttps://emergentbiosolutions.com/
Símbolo de cotizaciónEBS
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoPapa (Joseph C)
Ejecutivos de Emergent BioSolutions Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Emergent BioSolutions Inc?
Los cinco principales accionistas de Emergent BioSolutions Inc son: Mr. Joseph C. (Joe) Papa
¿Cuántas instituciones poseen acciones de Emergent BioSolutions Inc (EBS)?
A fecha de 2026Q1, 412 instituciones poseen acciones de Emergent BioSolutions Inc, con un valor de mercado combinado de aproximadamente 42.30M, lo que representa el 81.98% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3370363.00.
¿Cuál es la mayor fuente de ganancias de Emergent BioSolutions Inc?
El 2026Q1, el segmento empresarial MCM Product sales generó la ganancia más alta para Emergent BioSolutions Inc, ascendiendo a 168.00M y representando el 71.70% de la ganancia total.